Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.36
- Piotroski Score 4.00
- Grade Outperform
- Symbol (GH)
- Company Guardant Health, Inc.
- Price $36.89
- Changes Percentage (-0.59%)
- Change -$0.22
- Day Low $36.57
- Day High $37.80
- Year High $38.53
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $40.00
- High Stock Price Target $50.00
- Low Stock Price Target $36.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.92
- Trailing P/E Ratio -7.31
- Forward P/E Ratio -7.31
- P/E Growth -7.31
- Net Income $-479,449,000
Income Statement
Quarterly
Annual
Latest News of GH
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The Smartest Bitcoin ETF to Buy With $2,000 Right Now
Bitcoin has surged nearly 80% in the last three months, possibly due to a crypto-friendly administration under Trump. Government regulation impacts Bitcoin's market significantly, as seen with the SEC...
By Yahoo! Finance | 3 hours ago -
In Fight for Syria, a Battle for Domination of the Middle East
As rebels advance towards Damascus, Syria's authoritarian regime faces potential overthrow. Regional powers like Israel, Iran, and Turkey are involved, impacting global powers like the US and Russia. ...
By The New York Times | 3 hours ago -
Can Shiba Inu Reach $1 in 2025? The Answer Might Blow Your Mind.
Cryptocurrencies have seen significant growth in 2025, with Shiba Inu rising by over 180%. However, it remains 65% below its all-time high from 2021....
By Yahoo! Finance | 3 hours ago
